Boston Scientific Corporation (BSX) reported $21.07B of revenue for the twelve months ended Sep 30, 2026. That is up 8.9% from the year before. Revenue for fiscal 2025 was $20.07B.

Yes. Boston Scientific Corporation earned $3.50B in net income for the twelve months ended Sep 30, 2026, a net margin of 16.6%.

How much cash and debt does BSX have?

Boston Scientific Corporation reported $609.00M in cash and cash equivalents and $11.95B of debt on its most recent balance sheet in SEC filings.

How fast is BSX revenue growing?

Boston Scientific Corporation's revenue changed +19.9% in fiscal 2025, to $20.07B. Its compound annual growth rate was +15.2% over 5 years and +10.4% over 10 years.

What is BSX gross margin?

Boston Scientific Corporation's gross profit was $14.57B on $21.07B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 69.1%.

What is BSX free cash flow?

Boston Scientific Corporation generated $3.33B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $4.23B less capital expenditures.

What is BSX earnings per share?

Diluted earnings per share were $2.36 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did BSX last report financial results?

The latest statements here come from Boston Scientific Corporation's 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.

Financials · BSX

Boston Scientific Corporation (BSX) financials

For the twelve months ended Sep 30, 2026, Boston Scientific Corporation reported $21.07B of revenue and $3.50B of net income.

Revenue, TTM: $21.07B
Revenue growth, YoY: +8.9%
Net income, TTM: $3.50B
Net income growth, YoY: +25.5%
Net margin: 16.6%
Free cash flow, TTM: $3.33B
EPS, diluted, TTM: $2.36
EPS growth, YoY: +26.2%
Cash: $609.00M
Total debt: $11.95B
P/E: 17.69
P/S: 2.94
Market cap: $61.96B

Annual revenue$20.07B

FY2016FY2025

Annual net income$2.90B

FY2016FY2025

Annual free cash flow$3.66B

FY2016FY2025

BSX revenue and earnings growth

BSX revenueQ3 2026$5.14B

Quarter YoY: +1.4%
QoQ: -5.6%
FY YoY: +19.9%
5Y CAGR: +15.2%
10Y CAGR: +10.4%

BSX revenue was $5.14B in fiscal Q3 2026 (ended Sep 30, 2026), up 1.4% from a year earlier and down 5.6% from the prior quarter. For the full fiscal 2025 it was $20.07B, up 19.9% from fiscal 2024. Compound annual growth was +15.2% over 5 years and +10.4% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

BSX net incomeQ3 2026$582.00M

Quarter YoY: -22.9%
QoQ: -35.8%
FY YoY: +56.4%

BSX net income was $582.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 22.9% from a year earlier and down 35.8% from the prior quarter. For the full fiscal 2025 it was $2.90B, up 56.4% from fiscal 2024. It rose in 3 of the last 4 fiscal years.

BSX EPSQ3 2026$0.40

Quarter YoY: -21.6%
QoQ: -34.4%
FY YoY: +55.2%

BSX diluted EPS was $0.40 in fiscal Q3 2026 (ended Sep 30, 2026), down 21.6% from a year earlier and down 34.4% from the prior quarter. For the full fiscal 2025 it was $1.94, up 55.2% from fiscal 2024.

BSX free cash flowQ3 2026$868.00M

Quarter YoY: -25.3%
QoQ: -32.1%
FY YoY: +38.3%
5Y CAGR: +26.4%
10Y CAGR: +23.5%

BSX free cash flow was $868.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 25.3% from a year earlier and down 32.1% from the prior quarter. For the full fiscal 2025 it was $3.66B, up 38.3% from fiscal 2024. Compound annual growth was +26.4% over 5 years and +23.5% over 10 years. It rose in 4 of the last 6 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$20.07B	$16.75B	$14.24B	$12.68B	$11.89B	$9.91B	$10.73B	$9.82B	$9.05B	$8.39B
Cost of revenue	$6.22B	$5.26B	$4.34B	$3.96B	$3.71B	$3.46B	$3.12B	$2.81B	$2.59B	$2.42B
Gross profit	$13.85B	$11.49B	$9.90B	$8.73B	$8.18B	$6.45B	$7.62B	$7.01B	$6.46B	$5.96B
Research and development	$2.05B	$1.61B	$1.41B	$1.32B	$1.20B	$1.14B	$1.17B	$1.11B	$997.00M	$920.00M
Selling, general and admin	$6.89B	$5.98B	$5.19B	$4.52B	$4.36B	$3.79B	$3.94B	$3.57B	$3.29B	$3.10B
Operating income	$3.61B	$2.60B	$2.34B	$1.65B	$1.20B	-$80.00M	$1.52B	$1.51B	$1.28B	$447.00M
Interest expense	$349.00M	$305.00M	$265.00M	$470.00M	$341.00M	$361.00M	$473.00M	$241.00M	$229.00M	$233.00M
Pre-tax income	$3.38B	$2.28B	$1.99B	$1.14B	$1.08B	-$79.00M	$687.00M	$1.42B	$933.00M	$177.00M
Income tax	$493.00M	$436.00M	$393.00M	$443.00M	$36.00M	$2.00M	-$4.01B	-$249.00M	$828.00M	-$170.00M
Net income	$2.90B	$1.85B	$1.57B	$642.00M	$985.00M	-$115.00M	$4.70B	$1.67B	$104.00M	$347.00M
EPS, basic	$1.96	$1.26	$1.08	$0.45	$0.69	-$0.08	$3.38	$1.21	$0.08	$0.26
EPS, diluted	$1.94	$1.25	$1.07	$0.45	$0.69	-$0.08	$3.33	$1.19	$0.08	$0.25
Diluted shares	1.49B	1.49B	1.46B	1.44B	1.43B	1.42B	1.41B	1.40B	1.39B	1.38B

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$1.97B	$606.00M	$865.00M	$1.13B	$2.17B	$2.00B	$607.00M	$829.00M	$1.02B	$487.00M
Inventory	$2.94B	$2.81B	$2.48B	$1.87B	$1.61B	$1.35B	$1.58B	$1.17B	$1.08B	$955.00M
Current assets	$8.79B	$6.92B	$6.51B	$5.76B	$6.32B	$6.69B	$4.70B	$4.00B	$3.82B	$3.24B
Goodwill	$18.28B	$17.09B	$14.39B	$12.92B	$11.99B	$9.95B	$10.18B	$7.91B	$7.00B	$6.68B
Total assets	$43.67B	$39.40B	$35.14B	$32.47B	$32.23B	$30.78B	$30.57B	$21.00B	$19.04B	$18.10B
Current liabilities	$5.44B	$6.40B	$4.93B	$3.80B	$4.27B	$3.68B	$4.87B	$5.26B	$5.65B	$3.59B
Short-term debt	$299.00M	$1.78B	$531.00M	$20.00M	$261.00M	$13.00M	$1.42B	$2.25B	$1.80B	$64.00M
Long-term debt	$11.14B	$8.97B	$8.57B	$8.91B	$8.80B	$9.13B	$8.59B	$4.80B	$3.81B	$5.42B
Total debt	$11.44B	$10.75B	$9.10B	$8.94B	$9.06B	$9.14B	$10.01B	$7.06B	$5.62B	$5.48B
Total liabilities	$19.20B	$17.39B	$15.61B	$14.90B	$15.61B	$15.45B	$16.69B	$12.27B	$12.03B	$11.36B
Shareholders' equity	$24.23B	$21.77B	$19.53B	$17.57B	$16.62B	$15.33B	$13.88B	$8.73B	$7.01B	$6.73B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$4.53B	$3.44B	$2.50B	$1.53B	$1.87B	$1.51B	$1.84B	$310.00M	$1.43B	$1.18B
Capital expenditures	$876.00M	$790.00M	$711.00M	$588.00M	$554.00M	$376.00M	$461.00M	$316.00M	$319.00M	$376.00M
Free cash flow	$3.66B	$2.65B	$1.79B	$938.00M	$1.32B	$1.13B	$1.38B	-$6.00M	$1.11B	$806.00M
Investing cash flow	-$2.64B	-$5.69B	-$2.57B	-$2.01B	-$1.60B	-$411.00M	-$5.04B	-$1.92B	-$1.01B	-$887.00M
Financing cash flow	-$395.00M	$1.81B	$5.00M	-$548.00M	-$95.00M	$293.00M	$2.97B	$1.43B	$110.00M	-$206.00M
Dividends paid	-	$0	$28.00M	$55.00M	$55.00M	$28.00M	$0	$0	-	-
Share repurchases	-	-	-	$0	$0	$535.00M	$0	$0	-	$0
Stock-based compensation	$299.00M	$266.00M	$233.00M	$220.00M	$194.00M	$170.00M	$157.00M	$140.00M	$127.00M	$116.00M
Depreciation and amortization	$1.37B	$1.27B	$1.20B	$1.14B	$1.09B	$1.12B	$1.01B	$894.00M	$844.00M	$815.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	19.9%	17.6%	12.3%	6.7%	19.9%	-7.7%	9.3%	8.6%	7.9%	12.2%
Net income growth, YoY	56.4%	18.0%	144.5%	-34.8%	-	-	181.3%	1506.7%	-70.0%	-
EPS growth, YoY	55.2%	16.8%	137.8%	-34.8%	-	-	179.8%	1387.5%	-68.0%	-
Gross margin	69.0%	68.6%	69.5%	68.8%	68.8%	65.0%	71.0%	71.4%	71.3%	71.1%
Operating margin	18.0%	15.5%	16.5%	13.0%	10.1%	-0.8%	14.1%	15.3%	14.2%	5.3%
Net margin	14.4%	11.1%	11.0%	5.1%	8.3%	-1.2%	43.8%	17.0%	1.1%	4.1%
Free cash flow margin	18.2%	15.8%	12.6%	7.4%	11.1%	11.4%	12.8%	-0.1%	12.2%	9.6%
Return on equity	12.0%	8.5%	8.0%	3.7%	5.9%	-0.8%	33.9%	19.1%	1.5%	5.2%
Return on assets	6.6%	4.7%	4.5%	2.0%	3.1%	-0.4%	15.4%	8.0%	0.5%	1.9%
Current ratio	1.62	1.08	1.32	1.51	1.48	1.82	0.97	0.76	0.68	0.90
Debt to equity	0.47	0.49	0.47	0.51	0.55	0.60	0.72	0.81	0.80	0.81

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$5.14B	$5.44B	$5.20B	$5.29B	$5.07B	$5.06B	$4.66B	$4.56B	$4.21B	$4.12B	$3.86B	$3.73B
Cost of revenue	$1.71B	$1.59B	$1.59B	$1.61B	$1.52B	$1.64B	$1.45B	$1.47B	$1.31B	$1.27B	$1.21B	$1.15B
Gross profit	$3.43B	$3.85B	$3.61B	$3.68B	$3.54B	$3.42B	$3.21B	$3.10B	$2.90B	$2.85B	$2.65B	$2.58B
Research and development	$520.00M	$554.00M	$516.00M	$569.00M	$514.00M	$526.00M	$443.00M	$459.00M	$407.00M	$383.00M	$366.00M	$363.00M
Selling, general and admin	$1.68B	$1.80B	$1.78B	$1.83B	$1.74B	$1.72B	$1.60B	$1.61B	$1.56B	$1.45B	$1.36B	$1.38B
Operating income	$828.00M	$1.18B	$1.10B	$825.00M	$1.05B	$819.00M	$921.00M	$675.00M	$733.00M	$520.00M	$675.00M	$584.00M
Interest expense	$100.00M	$96.00M	$90.00M	$90.00M	$87.00M	$90.00M	$82.00M	$80.00M	$79.00M	$77.00M	$69.00M	$65.00M
Pre-tax income	$733.00M	$1.06B	$1.16B	$700.00M	$939.00M	$941.00M	$805.00M	$585.00M	$669.00M	$420.00M	$608.00M	$505.00M
Income tax	$153.00M	$155.00M	-$176.00M	$30.00M	$183.00M	$146.00M	$133.00M	$23.00M	$200.00M	$98.00M	$115.00M	$1.00M
Net income	$582.00M	$907.00M	$1.34B	$672.00M	$755.00M	$797.00M	$674.00M	$565.00M	$469.00M	$324.00M	$495.00M	$505.00M
EPS, basic	$0.40	$0.62	$0.90	$0.45	$0.51	$0.54	$0.46	$0.38	$0.32	$0.22	$0.34	$0.35
EPS, diluted	$0.40	$0.61	$0.90	$0.45	$0.51	$0.53	$0.45	$0.38	$0.32	$0.22	$0.33	$0.34
Diluted shares	1.45B	1.47B	1.50B	-	1.50B	1.49B	1.49B	-	1.49B	1.48B	1.48B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$609.00M	$539.00M	$1.45B	$1.97B	$1.27B	$534.00M	$725.00M	$606.00M	$2.50B	$2.91B	$2.33B	$865.00M
Inventory	$3.32B	$3.23B	$3.12B	$2.94B	$2.92B	$2.86B	$2.87B	$2.81B	$2.75B	$2.61B	$2.56B	$2.48B
Current assets	$8.16B	$7.97B	$8.68B	$8.79B	$8.04B	$7.12B	$7.33B	$6.92B	$8.76B	$8.99B	$8.19B	$6.51B
Goodwill	$18.74B	$18.64B	$18.54B	$18.28B	$18.21B	$18.08B	$17.34B	$17.09B	$15.03B	$14.40B	$14.36B	$14.39B
Total assets	$45.46B	$45.22B	$44.35B	$43.67B	$42.71B	$41.56B	$40.14B	$39.40B	$38.08B	$37.11B	$36.67B	$35.14B
Current liabilities	$5.98B	$6.43B	$4.57B	$5.44B	$5.33B	$5.19B	$5.06B	$6.40B	$5.91B	$5.58B	$4.92B	$4.93B
Short-term debt	$1.04B	$1.71B	$41.00M	$299.00M	$483.00M	$480.00M	$777.00M	$1.78B	$1.65B	$1.58B	$1.08B	$531.00M
Long-term debt	$10.91B	$10.91B	$10.99B	$11.14B	$11.12B	$11.11B	$10.53B	$8.97B	$9.23B	$8.99B	$9.53B	$8.57B
Total debt	$11.95B	$12.62B	$11.03B	$11.44B	$11.60B	$11.59B	$11.31B	$10.75B	$10.88B	$10.57B	$10.62B	$9.10B
Total liabilities	$19.59B	$20.04B	$18.25B	$19.20B	$19.08B	$18.91B	$17.69B	$17.39B	$17.12B	$16.50B	$16.50B	$15.61B
Shareholders' equity	$25.63B	$24.93B	$25.86B	$24.23B	$23.39B	$22.42B	$22.45B	$21.77B	$20.71B	$20.37B	$20.17B	$19.53B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$1.05B	$1.47B	$348.00M	$1.36B	$1.34B	$1.29B	$541.00M	$1.46B	$1.00B	$813.00M	$164.00M	$957.00M
Capital expenditures	$180.00M	$195.00M	$177.00M	$351.00M	$181.00M	$157.00M	$187.00M	$277.00M	$179.00M	$155.00M	$179.00M	$267.00M
Free cash flow	$868.00M	$1.28B	$171.00M	$1.01B	$1.16B	$1.13B	$354.00M	$1.18B	$823.00M	$658.00M	-$15.00M	$690.00M
Investing cash flow	-$437.00M	-$1.96B	-$591.00M	-$512.00M	-$502.00M	-$1.13B	-$500.00M	-$3.70B	-$1.43B	-$271.00M	-$285.00M	-$1.05B
Financing cash flow	-$569.00M	-$410.00M	-$260.00M	-$184.00M	-$104.00M	-$340.00M	$233.00M	$214.00M	$7.00M	$24.00M	$1.57B	$15.00M
Dividends paid	-	-	-	-	-	-	-	$0	$0	$0	$0	$0
Share repurchases	$0	-	-	-	$0	-	-	-	-	-	-	-
Stock-based compensation	$72.00M	$87.00M	$83.00M	$71.00M	$79.00M	$75.00M	$74.00M	$69.00M	$68.00M	$66.00M	$63.00M	$59.00M
Depreciation and amortization	$361.00M	$355.00M	$351.00M	$365.00M	$342.00M	$336.00M	$325.00M	$348.00M	$306.00M	$311.00M	$304.00M	$313.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	1.4%	7.5%	11.6%	15.9%	20.3%	22.8%	20.9%	22.4%	19.3%	14.5%	13.8%	14.9%
Net income growth, YoY	-22.9%	13.8%	99.0%	18.9%	61.0%	146.0%	36.2%	11.9%	-7.1%	24.1%	65.0%	300.8%
EPS growth, YoY	-21.6%	15.1%	100.0%	18.4%	59.4%	140.9%	36.4%	11.8%	-5.9%	22.2%	57.1%	277.8%
Gross margin	66.7%	70.7%	69.5%	69.6%	69.9%	67.7%	68.8%	67.9%	68.8%	69.2%	68.7%	69.2%
Operating margin	16.1%	21.6%	21.2%	15.6%	20.7%	16.2%	19.8%	14.8%	17.4%	12.6%	17.5%	15.7%
Net margin	11.3%	16.7%	25.8%	12.7%	14.9%	15.7%	14.5%	12.4%	11.1%	7.9%	12.8%	13.6%
Free cash flow margin	16.9%	23.5%	3.3%	19.2%	22.9%	22.3%	7.6%	25.8%	19.6%	16.0%	-0.4%	18.5%
Current ratio	1.36	1.24	1.90	1.62	1.51	1.37	1.45	1.08	1.48	1.61	1.66	1.32
Debt to equity	0.47	0.51	0.43	0.47	0.50	0.52	0.50	0.49	0.53	0.52	0.53	0.47

Source: XBRL data Boston Scientific Corporation files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BSX peers

Company	Revenue	Growth	Net income	Net margin	Market cap
BSX	$21.07B	+8.9%	$3.50B	16.6%	$61.96B
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
ABTAbbott Laboratories	$48.23B	+10.0%	$4.70B	9.7%	$190.39B
MDTMedtronic plc.	$37.54B	+9.8%	$5.24B	14.0%	$130.22B
SYKStryker Corporation	$26.30B	+7.9%	$3.62B	13.8%	$124.05B
BDXBecton Dickinson and Company	$23.25B	+17.4%	$941.00M	4.0%	$57.71B
BAXBaxter International Inc.	$11.61B	+5.3%	-$723.00M	-6.2%	$13.34B

BSX FAQ

9 questions

What is BSX revenue?
Boston Scientific Corporation (BSX) reported $21.07B of revenue for the twelve months ended Sep 30, 2026. That is up 8.9% from the year before. Revenue for fiscal 2025 was $20.07B.
Is BSX profitable?
Yes. Boston Scientific Corporation earned $3.50B in net income for the twelve months ended Sep 30, 2026, a net margin of 16.6%.
How much cash and debt does BSX have?
Boston Scientific Corporation reported $609.00M in cash and cash equivalents and $11.95B of debt on its most recent balance sheet in SEC filings.
How fast is BSX revenue growing?
Boston Scientific Corporation's revenue changed +19.9% in fiscal 2025, to $20.07B. Its compound annual growth rate was +15.2% over 5 years and +10.4% over 10 years.
What is BSX gross margin?
Boston Scientific Corporation's gross profit was $14.57B on $21.07B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 69.1%.
What is BSX free cash flow?
Boston Scientific Corporation generated $3.33B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $4.23B less capital expenditures.
What is BSX earnings per share?
Diluted earnings per share were $2.36 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did BSX last report financial results?
The latest statements here come from Boston Scientific Corporation's 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
Where does this BSX financial data come from?
Quantisnow builds these statements from the structured XBRL data Boston Scientific Corporation files with the SEC. It is provided for information only and is not investment advice.